A Phase 3, Open-Label, Multicenter Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease (CAD)
Flurpiridaz (18F) for PET Assessment of Myocardial Perfusion in Patients Of Suspected Coronary Artery Disease (CAD)
Sponsor: GE Healthcare
Enrolling: Male and Female Patients
Clinic Visits: 2
IRB Number: AAAR8795
U.S. Govt. ID: NCT03354273
Contact: Kate Dalton: 347-514-3366 / keb2114@cumc.columbia.edu
Additional Study Information: Phase 3 open-label, multicenter Study of Flurpiridaz Injection for PET Imaging for assessment of Myocardial perfusion in patients referred for Invasive Coronary Angiography because of suspected Coronary Artery Disease
Investigator
Andrew Einstein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Kate Dalton
keb2114@cumc.columbia.edu
347-514-3366